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Summary The presence of tumour cells in the blood circulation may predict disease recurrence and metastasis. We have evaluated the
specificity and sensitivity of detecting hepatoma cells in blood using nested polymerase chain reaction with primers specific for the
alphafetoprotein (AFP) gene. The nested polymerase chain reaction amplified a 270-base pair AFP DNA fragment from cDNA of Hep 3B
hepatoma cells. In a reconstitution experiment, AFP mRNA was detected from peripheral mononuclear cells isolated from 10 ml of blood
containing as few as ten Hep 3B cells. Peripheral mononuclear cells from the blood of 20 hepatoma patients were analysed, and 19 patients
showed positive AFP mRNA expression. Seven of 13 samples from hepatitis patients also showed positive AFP mRNA expression. All five
paired samples of peripheral blood or umbilical cord blood from pregnant mothers and their babies, respectively, showed positive AFP
expression. None of 22 control samples was positive. The presence of AFP mRNA in the blood of hepatitis or hepatoma patients suggests the
presence of circulating hepatoma cells or hepatocytes in the circulation. The high incidence of AFP mRNA in the blood of hepatoma patients
supports the notion of early haematogenous spreading of the disease.
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Hepatocellular carcinoma (HCC) is one of the most common
malignancies in Taiwan, mainland China and southern Africa. The
disease is highly associated with hepatitis B and C virus infections
as well as with the carcinogen aflatoxin (Chen, 1987). Despite
improved survival of some cancer patients in recent years, the
therapeutic efficacy for HCC remains very limited. Survival after
the onset of symptoms is only a few months (Lai et al, 1987). It
is therefore important to establish techniques for the early diag-
nosis ofHCC.
Alphafetoprotein (AFP) is a glycoprotein that is normally
expressed during embryogenesis. The concentration of AFP in
serum decreases as the liver develops and matures. However, AFP
levels can become elevated in some disease states, particularly in
HCC (Bellet et al, 1985; Chen, 1987; Di Bisceglie and Hoofnagle,
1989). Elevated serum AFP is employed as a highly specific and
sensitive marker for the diagnosis of HCC, as about 82% of HCC
patients have elevated serum AFP levels (Bellet et al, 1985).
However, AFP can also be elevated in non-malignant forms of
liver disease, such as acute and chronic hepatitis and cirrhosis
(Chen, 1987; Di Bisceglie and Hoofnagle, 1989). In addition,
increasing AFP levels have also have been associated with liver
regeneration (Silver et al, 1974).
A major characteristic ofcancer is the ability oftumour cells to
metastasize to other sites. The process of tumour metastasis
involves multiple host-tumour interactions, and it is thought that
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less than 0.01% of circulating tumour cells successfully establish
metastatic colonies (Liotta and Stetler-Stevenson, 1991). Similar
to other cancer types, HCC cells frequently metastasize to the
lung, lymph nodes and bone (Chen, 1987). To understand stage
tumourprogression better, several laboratories have reported using
the polymerase chain reaction (PCR) to detect metastatic cells in
peripheral blood or lymph nodes (Johnsum et al, 1995). These
studies made use of the detection of mRNA expression of tissue-
specific antigens (Natio et al, 1991; Smith et al, 1991; Mattano et
al, 1992; Moreno et al, 1992; Deguchi et al, 1993; Hillaire et al,
1994; Israeli et al, 1994; Matsumura et al, 1994, 1995; Schoenfeld
et al, 1994; Kar and Carr, 1995; Komeda et al, 1995) and the
metastatic-associated antigen CD44 (Matsumura et al, 1992).
For HCC, reverse transcription PCR (RT-PCR) has been
used to detect albumin and AFP expression in the blood of HCC
and hepatitis patients (Hillaire et al, 1994; Matsumura et al,
1994-1995; Kar and Carr, 1995; Komeda et al, 1995). Positive
albumin and AFP expression in the blood was found to be associ-
ated with early subsequent relapse (Hillaire et al, 1994; Komeda et
al, 1995). We have attempted to detect AFP mRNA expression by
means of nested PCR to diagnose haematogenous metastasis in
patients with HCC. Samples from hepatitis and control patients as
well as normal volunteers were used to define the specificity of
AFP mRNA detection in blood samples.
MATERIALS AND METHODS
Cell culture and lymphocyte separation from blood
The Hep 3B human HCC cell line, which secretes AFP, was used as
a control to define the assay sensitivity. The cell line was kindly
provided by Dr Cheng-Po Hu (Veterans General Hospital, Taipei,
Taiwan) (Knowles etal, 1980). Cells were maintained inRPMI-1640
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Table 1 Characteristics of HCC patients and detection of AFP mRNA in
samples from peripheral mononuclear cells
Patient No. of lesions Tumour sizeb Serum AFPc AFP mRNAd
no. in the liver (ng ml-')
1 3 M 80 000 +
2 1 M 17 950 +
3 5 M 11 585 +
4 7 S-M 6534 +
5 1 L 6911 +
6 1 M 6 244 +
7 4 L 5 330 +
8 1 L 5135 +
9 7 M 4437 +
10 6 S-M 3631 +
11 1 S 1 551 +
12 1 S 853 +
13 1 L 709 +
14 1 M 435 +
15 3 S-M 171 +
16 2 M 83.2 +
17 3 S-M 60.0 +
18 1 L 46.3 +
19e 6 L 35.9 +
20 2 S-M 4.5 -
eLung metastasis. aDetermined by CT scan. bSmall (S), < 3 cm; medium (M),
3-10 cm; large (L), > 10 cm. cDetermined by radioimmunoassay.
dDetermined by nested PCR.
Table 2 Characteristics of hepatitis patients and detection of AFP mRNA in
samples from peripheral mononuclear cells
Patient Clinical Serum AFP AFP mRNA
no. diagnosis (ng ml-')
1 Chronic hepatitis B 3091 +
2 Chronic hepatitis B 388 +
3 Chronic hepatitis B 242 +
4 Chronic hepatitis B 67.8
5 Chronic hepatitis B 59.1 +
6 CPH 35.4 +
7 CAH 28.0 -
8 CPH 27.0 -
9 Chronic hepatitis B 11.4 -
10 Chronic hepatitis B 9.7 -
11 CAH 7.8 +
12 Acute hepatitis A 3.5 +
13 Acute hepatitis A 6.2
CPH, chronic persistent hepatitis; CAH, chronic active hepatitis.
medium supplemented with 25 mm Hepes, 26 mm sodium bicar-
bonate, 2 mm glutamine, 100 ,u mln- penicillin, 100 jg ml-' strepto-
mycin and 10% fetal bovine serum at 370C with 5% carbon dioxide.
All tissue culture reagents and medium were obtained from Gibco
(Gibco BRL Life Technologies, Gaithersburg, MD, USA). Cells
were free of mycoplasma as tested with Hoechst 33258 dye (Sigma
Chemical Co., St Louis, MO, USA).
Peripheral mononuclear cells that may contain tumour cells
were isolated from 10-ml samples of blood following discontin-
uous gradient centrifugation using Ficoll-Paque (Pharmacia,
Uppsala, Sweden). After washing twice with phosphate-buffered
saline, the cell pellets were snap frozen in liquid nitrogen and then
stored at-1300C.
Samples ofperipheral mononuclear cells were isolated from 20
patients with HCC as well as from two patients with cholangiocar-
cinoma, one with gall bladder carcinoma, one with colon cancer
with liver metastasis, 11 with chronic hepatitis B, two with acute
hepatitis A and 18 healthy volunteers. In addition, blood samples
from five pregnant women obtained during labour as well as the
umbilical cord blood oftheir babies were also collected. HCC was
diagnosed based on either ofthe following two criteria. First, liver
biopsy specimens were pathologically diagnosed. Second, patients
had serum AFP levels higher than 20 ng ml-'; serum samples were
positive for HBsAg or anti-HCV; and tumour lesions were
observed in the liver from at least two imaging studies including
computerized tomography (CT) scan, abdominal sonography and
angiography. Tables 1 and 2 summarize information from the HCC
and hepatitis patients respectively. The sizes and numbers of
primary lesions, serum AFP levels and presence of distant meta-
stasis are shown. Serum AFP values from pregnant women and
their babies ranged from 45 to 166 ng ml-' and 3005 to 5436 ng
ml-' respectively. The serum AFP levels of the other control
samples were less than 8 ng ml-'.
RNA preparation
Poly (A)+ RNA was prepared as described by Badley et al (1988).
Cells were lysed in buffer containing 0.2 M sodium chloride, 0.2 M
Tris-HCl, pH 7.5, 1.5 mm magnesium chloride, 2% sodium dodecyl
sulphate (SDS), 200 jig ml-' protease K and 50 gM aurin tricarbo-
xylic acid (Sigma) and incubated at 45°C for 2 h. Cell lysates were
then incubated with oligo-dT cellulose (Boehringer Mannheim,
Germany) in the same buffer containing 0.5 M sodium chloride at
room temperature for 1 h on a rotatory shaker. After washing, RNA
was eluted with 0.01 M Tris-HCl, pH 7.5, and precipitated. RNA
was dissolved in diethyl pyrocarbonate-treated water.
Polymerase chain reaction
Synthesis of cDNA from 1 jg of mRNA isolated from Hep 3B
cells or all the mRNA isolated from the peripheral mononuclear
cells in 10 ml of blood was carried out in a 20-jil reaction using a
first-strand cDNA synthesis kit (Gibco BRL) by following the
manufacturer's instructions. Nested PCR was conducted by adding
5 jil ofcDNA to 100 jl ofreaction mixture containing 10 mm Tris-
HCl (pH 9.0), 50 mm potassium chloride, 4.5 mm magnesium
chloride, 250 nm dNTP, 460 nm of each outer primer and 2.5 units
of Taq DNA polymerase (Promega, Madison, WI, USA). The
reaction mixtures were subjected to 35 cycles ofamplification in a
programmable thermal cycler (Perkin-Elmer Cetus, Norwalk, CT,
USA) by using the following sequence: 94°C for 1.5 min, 57°C for
1.5 min and 72°C for 2.5 min, plus a final extension step at 72°C
for 10 min. A sample of 10 jl of the first amplification product
was further amplified using an inner pair ofprimers. To verify the
amplified AFP DNA fragment, samples were digested with the
restriction enzyme PstI and analysed by electrophoresis on a 2%
agarose gel. To verify the successful preparation of mRNA,
samples were detected for the presence ofglyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) mRNA by RT-PCR under the
same conditions described above. Reaction tubes containing
cDNA from Hep 3B cells, peripheral mononuclear cells ofhealthy
volunteers or without cDNA addition were included as positive or
negative control for each PCR reaction. Nested PCR was
conducted two or three times for samples with conflicting results
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between serum AFP levels and AFP mRNA as determined by
nested PCR.
Two pairs of PCR primers derived from the published AFP
cDNA sequence (Morinaga et al, 1983) were used to detect AFP
mRNA expression. The outer pair of primers were AFP-S1 (5'-
GCCCAGTTTGTTCAAGAAGCC-3', nucleotides 198-218) and
AFP-AS1 (5'-TllTTGTCATAGCGAGCAGCCC-3', nucleotides
586-606). The inner pair of primers were AFP-S2 (5'-
CAGTCTTCAGGGTGTITTAGAA-3', nucleotides 288-308) and
AFP-AS2 (5'-GGGATGCCTTCTTGCTATCTC-3', nucleotides
537-557). The primers to detect GAPDH mRNA expression were
GAP-SI (5'-GTCAAGGCTGAGAACGGGAAG-3', nucleotides
172-192) and GAP-AS1 (5'-TAGACGGCAGGTCAGGTCCAC-
3', nucleotides 721-741) (Tso et al, 1985).
Quantitation of AFP mRNA
To introduce a new restriction enzyme site (XbaI) in the middle of
the amplified AFP product, the 194- and 244-base pair AFP DNA
fragments were first amplified from Hep 3B cDNA using primers
AFP-SI and AFP-mAS (5'-TGGCTGCAGCAGTCTAGAATGTC-
CGTACTTC-3', nucleotides 362-392) and primers AFP-mS (5'-
GAAGTACGGACATTCTAGACTGCTGCAGCCA-3',
nucleotides 362-392) and AFP-AS1, respectively, at 64°C for 1.5
min and 72°C for 2.5 min for 35 cycles. The fragments were puri-
fied, mixed, extended with Klenow enzyme and further amplified
using primers AFP-Sl and AFP-AS1. The 409-base pair DNA frag-
ment containing an internal XbaI restriction site was then purified,
quantified and used as the internal standard for quantitative
PCR assay.
To quantitate AFP mRNA, serial dilutions (103 to 10ll copies) of
the internal standard were added to each PCR mixture containing
10 ng ofHep 3B cDNA. The mixture was first amplified using the
outer pair of primers followed by nested PCR using the internal
pair of primers as described above. The amplified product was
digested with XbaI and electrophoresed on 3% agarose gel. Three
bands of 270 (wild-type), 181 and 89 bp (both derived from the
internal standard) were visible. The amount of AFP mRNA was
calculated by comparing the intensities ofthe wild-type AFP band
with the internal control bands (summation of the two bands)
(Figure 2).
RT- PCR
M N B 1 2 3 4 5
Nested - PCR
1 2 3 4 5
4- 409
- 270
Figure 1 Comparison of the sensitivities of RT-PCR and nested PCR. Hep
3B cDNA (1 gg) was tenfold serially diluted to 1 pg, and samples containing
10 ng (lane 1), 1 ng (lane 2), 100 pg (lane 3), 10 pg (lane 4) or 1 pg (lane 5)
of cDNA were used for both RT-PCR and nested PCR. The amplified AFP
DNA fragments with sizes of 409 and 270 base pairs are indicated on the
right. Lane M, 100-base pair DNA marker (Promega); lane N, peripheral
mononuclear cells from a healthy volunteer; lane B, blank (no cDNA added)




Figure 2 Quantitation of AFP mRNA in Hep 3B cells. PCR mixture
containing 10 ng of Hep 3B cDNA and 103 to 1011 copies of internal standard
(lane 1-9) was used for nested PCR as described in Materials and methods.
Samples were then digested with Xbal. The 270-bp DNA fragment was
derived from the Hep 3B cDNA, and the 181-and 89-bp fragments were
derived from the internal standard. Lane P, without internal standard added;
lane M, 100-base pair marker (Promega, WI, USA)
Southern blot analysis
PCR products were fractionated on a 1.2% agarose gel in 45 mM
Tris-borate pH 8.0, 1 mM EDTA buffer solution and denatured in
1.5 M sodium chloride, 0.5 N sodium hydroxide before transfer to a
nylon membrane (Boehringer Mannheim) by capillary blotting in
20 x saline sodium citrate (SSC) (3 M sodium chloride, 0.3 M
sodium citrate, pH 7.0). The blots were UV-fixed, prehybridized
and hybridized at 42UC in buffer containing 50% (v/v) formamide,
5 x SSC, 2% (w/v) blocking reagent (Boehringer Mannheim),
0.1% N-lauroylsarcosine and 0.02% (w/v) SDS. The membranes
were washed with 2 x SSC containing 0.1% SDS and washed
again with 0.1 x SSC containing 0.1% SDS at 68°C for 30 min.
Specific hybridization was detected by a DIG luminescent detec-
tion kit using lumigen-PPD as the substrate (Boehringer
Mannheim). The intensity of luminescence was recorded using
Kodak XAR-5 film at room temperature. The PstI-digested 0.16,
0.23, 0.31, 0.5 kb cDNAs encoding human AFP were isolated
from plasmid pHAF7 (American Type Culture Collection,
Rockville, MD, USA) and were labelled with digoxigenin using a
DNA labelling kit (Boehringer Mannheim).
RESULTS
We first studied the feasibility ofusing nested PCR to detect AFP
mRNA expression in Hep 3B hepatoma cells. The sense and anti-
sense primers located within exons 3 and 5, respectively, were
designed to eliminate the possibility of false positives generated
from DNA contamination (Gibbs et al, 1987). RT-PCR carried out
with the outer pair ofAFP primers amplified a 409-base pair DNA
fragment from mRNA isolated from Hep 3B cells. Nested PCR
using both outer and inner pairs of primers amplified a 270-base
pair AFP DNA fragment (Figure 1). The amplified AFP DNA
fragments showed correct restriction fragment length following
digestion withPstI enzyme. Furthermore, the identity ofthe ampli-
fied AFP DNA fragments was confirmed by Southern blot analysis
(data not shown).
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Figure 3 Sensitivity of nested PCR for detection of AFP mRNA in a
reconstitution experiment. Peripheral mononuclear cells from 10 ml of blood
from a healthy volunteer were mixed with 10 000 (lane 1), 5000 (lane 2),
1000 (lane 3), 500 (lane 4), 250 (lane 5), 100 (lane 6), 50 (lane 7), 10 (lane
8), 5 (lane 9) or 1 (lane 10) Hep 3B cells. Poly A+ RNA and cDNA were
prepared. Nested PCR, using primers for AFP, and RT-PCR, using primers
for GAPDH, were then conducted. The 270-and 570-base pairfragments
represent amplified AFP or GAPDH DNA respectively. Lane P, positive
control (Hep 3B cells); lane B, blank (no cDNA added); lane M, 100-base pair
marker (Gibco BRL)
The sensitivity of the assay was determined in two ways. The
sensitivities ofRT-PCR and nested PCR were comparedby ampli-
fying the AFP gene in serial dilutions of Hep 3B cells. Figure 1
shows that nested PCR was about 100-fold more sensitive than
RT-PCR. Specific AFP mRNA was detected by nested PCR in
samples containing 10 pg ofHep 3B cDNA. RT-PCR, in contrast,
amplified AFP DNA only from samples containing more than 1 ng
of Hep 3B cDNA. The sensitivity of RT-PCR could be made as
sensitive as nested PCR by employing Southern blot analysis of
the RT-PCR product (data not shown). By using semi-quantitative
PCR, 107 AFP molecules were detected in 10 ng ofHep 3B cDNA
(Figure 2). Specific AFP mRNA was detected in 10 pg of Hep 3B
cDNA. Therefore, nested PCR could detect AFP mRNA in
samples containing as few as 104 AFP mRNA molecules. Since
nested PCR had the advantages of simple usage and high sensi-
tivity, we used nested PCR to detect AFP mRNA in all the
following studies.
The sensitivity of nested PCR for detecting tumour cells in
blood was simulated by amplifying cDNA prepared from samples
containing Hep 3B cells and peripheral mononuclear cells from a
healthy volunteer in different mixing ratios (Figure 3). AFP
mRNA could be detected in the cDNA prepared from peripheral
mononuclear cells of 10 ml of blood containing ten or more Hep
3B cells. The presence of intact mRNA in all tested samples was
confirmed by amplifying a 570-base pair DNA fragment of
GAPDH using RT-PCR.
The applicability of using nested PCR to detect circulating
AFP-expressing cells was investigated in 45 peripheral blood
samples from patients with HCC, colon cancer with liver metas-
tasis, cholangiocarcinoma or hepatitis patients as well as from
healthy volunteers. GAPDH was expressed at relatively high
levels in various cell types and nested PCR had 100-fold higher
sensitivity than RT-PCR. Therefore, only samples showing posi-
tive GAPDH DNA amplification by RT-PCR were used to
analyse the presence ofAFP mRNA using nested PCR.
Among 20blood samples fromHCC patients, 19 samples showed
positive AFP mRNA expression in the peripheral mononuclear cells





Figure 4 Detection of AFP mRNA in the blood of representative patients and
healthy volunteers using nested PCR. Lane M, 100-base pair marker; lane P,
positive control (Hep 3B cells); lane N, negative control (peripheral
mononuclear cells from a healthy volunteer); lanes A - F, HCC patients 1, 6,
12, 16, 17 and 20 as described in Table 1; lane G -J, hepatitis patients 2, 3,
6 and 9 as shown in Table 2; lane K, cholangiocarcinoma; lane L, colon
cancer metastatis to the liver; lanes 0 and Q, healthy volunteers. The + or -
mark shown on the bottom of the figure represents the presence or absence
of amplified AFP DNA
(Table 1). Amongthepatients withpositive AFPmRNAexpression,
the number of primary tumours varied from one to seven and
tumour sizes ranged from small to large. The 270-base pair AFP
DNA fragment amplified from representative HCC samples is
shown in Figure 4. All AFP mRNA-positive samples were derived
from patients with serum AFP levels higher than 20 ng ml-',
including patient 19 with lung metastasis. Only patient 20, who had
a low level of serum AFP (4.5 ng ml-') exhibited negative AFP
mRNA detection in peripheral mononuclear cells.
Thirteen samples of peripheral mononuclear cells from patients
with chronic active hepatitis, chronic persistent hepatitis, unclassi-
fied chronic hepatitis B or acute hepatitis A were also analysed
(Table 2, Figure 4). Samples from 7 of 13 (46%) hepatitis patients
showed positive AFP mRNA expression. Among these positive
samples, five had serum AFP levels higherthan 20 ng ml-', whereas
two patients (11 and 12) had low serum AFP levels (7.8 and 3.5 ng
ml-1 respectively). However, three patients with negative AFP
mRNA detection in their peripheral mononuclear cells had serum
AFP levels higher than 20 ng ml-' (67.8, 28.0 and 27.0 ng ml-').
Peripheral mononuclear cells from two patients with cholangio-
carcinoma, one patient with gall bladder carcinoma, one patient
with colon cancer metastasis to the liver, five pregnant women
during labour and umbilical cord blood from their babies and 18
healthy volunteers were analysed. The five paired samples from
the pregnant women and their babies, which had increased serum
AFP protein levels, all showed positive AFP mRNA in their
peripheral mononuclear cells (data not shown). However, none of
the control samples that had serum AFP levels less than 8 ng ml-'
showed positive AFP mRNA expression in the peripheral
mononuclear cells using nested PCR (Figure 4).
We have demonstrated that nested PCR with primers specific for
AFP cDNA can amplify a 270-base pair DNA fragment from Hep
3B hepatoma cells. This technique is 100-fold more sensitive than
RT-PCR and can detect AFP gene expression in ten Hep 3B cells
among the peripheral mononuclear cells isolated from 10 ml of
blood. AFP mRNA expression was observed in peripheral
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mononuclear cells prepared from most HCC patients, some
hepatitis patients and all pregnant women and their newborn
babies.
The use ofRT-PCR alone or in combination with Southern blot
analysis to detect tumour cells in the blood circulation has been
described previously. Tissue-specific antigens (such as albumin,
AFP, tyrosinase, prostate-specific antigen and tyrosine hydroxy-
lase), the neuroendocrine protein, keratin 19, and the metastatic-
associated antigen CD44 have been used as marker genes to detect
tumour micrometastasis in the blood, bone marrow or lymph
nodes (Naito et al, 1991; Smith et al, 1991; Matsumura and Tarin,
1992; Mattano et al, 1992; Moreno et al 1992; Deguchi et al, 1993;
Hillaire et al, 1994; Israeli et al, 1994; Matsumura et al, 1994,
1995; Schoenfeld et al, 1994; Kar and Carr, 1995; Komeda et al,
1995). The detection sensitivities ranged from one tumour cell per
105 to 107 normal cells (Johnsum et al, 1995). By using nested
PCR, we could detect AFP mRNA expression in 10 pg of Hep 3B
cDNA that contained about 104 AFP mRNA molecules or ten Hep
3B cells in the peripheral mononuclear cells isolated from 10 ml of
blood. The sensitivity of our assay is equivalent to or more sensi-
tive than other reported studies. Our results imply that, with our
detection system, a single tumour cell among 5 x 106 to 107 normal
peripheral mononuclear cells can be detected. Patients may have
105 or more tumour cells in their circulation when AFP mRNA
was detected by the nested PCR. Comparison ofthe sensitivities of
RT-PCR and nested PCR revealed that nested PCR provided 100-
fold better sensitivity (Matsumura et al, 1995). Furthermore,
nested PCR has increased specificity owing to the use of two pairs
of specific primers. Therefore, nested PCR is superior to RT-PCR
with respect to specificity and sensitivity for the detection of
micrometastatic tumour cells.
The clinical applicability of PCR for the detection of
micrometastatic hepatoma cells has been documented by evalu-
ating blood samples from patients (Hillaire et al, 1994; Matsumura
et al, 1994, 1995; Kar and Carr, 1995; Komeda et al, 1995).
Albumin and AFP have been employed as target genes for
hepatoma detection. About 36-59% of blood samples from HCC
patients showed positive albumin or AFP mRNA expression.
RT-PCR using primers for albumin could detect circulating cancer
cells in hepatoma patients, which was associated with poor patient
prognosis and advanced stages of the disease (Hillaire et al, 1994;
Kar and Carr, 1995). Similarly, positive detection of AFP mRNA
in blood was associated with tumour size, tumour volume, serum
AFP levels, intrahepatic or distant metastasis (Matsumura et al,
1994; Komeda et al, 1995). Similar to previous studies, we
detected AFP mRNA in all blood samples from HCC patients with
intrahepatic or distant metastasis. The high positive detection rate
(95%) of AFP mRNA in the blood of HCC patients may have
resulted from the fact that 90% of the patients investigated in this
study had advanced HCC with either multiple intra-hepatic foci,
large sizes ofprimary tumours or distant metastasis. However, two
HCC patients with small tumours and high levels of AFP (1551
and 853 ng ml-1) exhibited AFP mRNA expression, suggesting
that haematogenous spread ofHCC cells had occurred in these two
patients. The only HCC patient with negative AFP mRNA had low
levels of serum AFP. The failure to detect AFP mRNA in this
sample could have been caused by the lack or extremely low levels
of AFP gene expression in the HCC tumour cells of this patient.
This study implies that haematogenous spreading of HCC cells
occurs very early. This should be confirmed by increasing the
number ofpatients with early stages ofHCC.
Although AFP is a tumour-associated antigen, it is not specific
for hepatoma. Increased serum AFP levels are associated with
hepatocyte regeneration and are observed in patients with acute or
chronic hepatitis (Silver et al, 1974; Chen, 1987; Di Bisceglie and
Hoofnagle, 1989). Similar to the observations of Hillaire et al
(1994) and Matsumura et al (1994) we detected AFP mRNA, indi-
cating the presence of AFP-expressing cells, in the blood of some
patients with chronic or acute hepatitis. As samples from patients
with cholangiocarcinoma, colon cancer with liver metastasis or
healthy volunteers did not show positive AFP mRNA amplifica-
tion, the circulating AFP-expressing cells from hepatitis patients
may be derived from regenerating hepatocytes (Hillaire et al,
1994) or from injured, necrotic hepatocytes (Matsumura et al,
1994). However, we believe that this is less likely, as mRNA is
unstable in blood (Pfleiderer et al, 1995). When the profiles of
serum SGOT and SGPT levels from hepatitis patients were
analysed, liver regeneration was suggested in some patients with
positive AFP mRNA expression in the peripheral mononuclear
cells (data not shown). Also, AFP-expressing cells were detected
in one patient with acute hepatitis A. Therefore, the detection of
AFP mRNA in these patients is probably caused by the presence of
AFP-expressing cells in the circulation owing to some regenera-
tive phenomenon. To our knowledge, it is not known whether
regenerating hepatocytes are released into the blood circulation.
However, the level of hepatocyte growth factor, which is thought
to play a role in liver regeneration, increases in hepatitis patients
during liver regeneration (Hioki et al, 1993). In addition to stimu-
lating hepatocyte proliferation, hepatocyte growth factor, also
known as 'scatter factor', can induce dissociation and increase
local cell motility of a variety ofepithelial cells, including hepato-
cytes (Jiang et al, 1993; Stolz et al, 1994). Whether the presence of
factors, such as hepatocyte growth factor, which increases the
motility of hepatocytes, leads to the circulation of hepatocytes in
hepatitis patients remains to be clarified. In this study, we detected
AFP mRNA in two samples that had low serum AFP protein
levels. This result may have been caused by a higher sensitivity of
nested PCR compared with the radioimmunoassay used to detect
serum AFP. In addition, the expression of heterogeneous AFP
molecules, such as the non-secreted form ofAFP (Hosokawa et al,
1989) could also lead to this result.
Studies by Hillaire et al (1994) have shown that hepatitis
patients with positive detection of albumin mRNA in blood
samples have poor prognosis. Whether the presence of AFP
mRNA-expressing cells in some hepatitis patients, as found in the
present study, indicates the presence of early-stage HCC tumours
and poor prognosis remains to be defined. The presence of AFP
mRNA in blood may not specifically indicate the presence ofHCC
cells. Therefore, identification of tumour-specific genes for
hepatoma is very important for the molecular diagnosis of the
haematogenous metastasis ofhepatoma cells.
The AFP gene is a tumour-associated gene. Most normal tissues
do not express AFP. It is primarily expressed in liver cells, as well
as in the gut, stomach, trophoblast, lung or pancreas and to a lesser
extent in the fetus and newborn infant (Shi et al, 1985; Nahon et al,
1988). It is not known whether AFP is expressed by the
haematopoietic cells in fetal blood. However, Esteban et al (1993)
have shown by in situ hybridization that activated monocytes and
lymphocytes from adults express AFP mRNA. The positive AFP
mRNA expression detected in all five samples of umbilical cord
blood may have been caused by the expression of AFP mRNA by
peripheral mononuclear cells or by trophoblast cells that were shed
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in the blood during delivery. The blood barrier in the placenta that
separates the blood circulation of the fetus and mother is incom-
plete. Some molecules, viruses and cells can cross the barrier and
circulate in the blood of the mother and fetus (Adkison et al,
1994). This may explain why all five blood samples from pregnant
women had positive AFP mRNA expression.
In summary, we have described a PCR-based technique that can
detect circulating hepatoma cells or hepatocytes in patients with
HCC or hepatitis. This method may detect extra-hepatic metastatic
tumour cells in the blood earlier than traditional imaging methods
in HCC patients. Because ofthe expression ofAFP by non-tumour
cells and the potential presence of circulating AFP-expressing
hepatocytes in hepatitis patients, the use of HCC-specific marker
genes in combination with nested PCR is necessary to provide an
early, sensitive and specific diagnostic method for the clinical
staging of HCC.
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